Longitudinal Study of the Porphyrias

Description

The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.

Conditions

Acute Porphyrias, Cutaneous Porphyrias

Study Overview

Study Details

Study overview

The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.

Longitudinal Study of the Porphyrias

Longitudinal Study of the Porphyrias

Condition
Acute Porphyrias
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama, Birmingham, Birmingham, Alabama, United States, 35294

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Miami

University of Miami, Miami, Florida, United States, 33136

Chicago

University of Illinois at Chicago, Chicago, Illinois, United States, 60637

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

New York

Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029

Charlotte

Carolinas Medical Center and HealthCare System, Charlotte, North Carolina, United States, 28203

Winston-Salem

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States, 27106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals with a documented diagnosis of a porphyria.
  • * For each type of porphyria, the inclusion criteria are based on
  • * Biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing performed after 1980 (Absolute values are preferred for diagnostic biochemical thresholds. Fold increases in comparison to an upper (or lower) limit of normal (ULN or LLN) are also acceptable, but are complicated by considerable variation between laboratories in normal limits. Equivocal biochemical measurements may require confirmation by a consortium reference laboratory;)
  • * molecular findings documenting the identification of a mutation in a porphyria-related gene.
  • * In addition, an individual or a parent or guardian must be willing to give written informed consent or assent, as appropriate.
  • * Provision is made for enrolling relatives who may not have symptoms but have biochemical or molecular documentation of a porphyria, or in the case of recessive disorders carry a disease-related mutation.
  • * Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone marrow diseases;
  • * Patients with a prior diagnosis of porphyria that cannot be documented by review of existing medical records or repeat biochemical or DNA testing.

Ages Eligible for Study

1 Minute to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Icahn School of Medicine at Mount Sinai,

Manisha C Balwani, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

2025-06